Next Article in Journal
The Metabolome and Osteoarthritis: Possible Contributions to Symptoms and Pathology
Previous Article in Journal
Prospective Biomarkers from Plasma Metabolomics of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Implicate Redox Imbalance in Disease Symptomatology
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessArticle
Metabolites 2018, 8(4), 91; https://doi.org/10.3390/metabo8040091

Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts

1
Metabolomics Unit, College of Veterinary Medicine, Lincoln Memorial University, 6965 Cumberland Gap Pkwy, Harrogate, TN 37752, USA
2
Department of Medicine, DeBusk College of Osteopathic Medicine, Lincoln Memorial University, 6965 Cumberland Gap Pkwy., Harrogate, TN 37752, USA
3
Laboratory of Multidisciplinary Research, São Francisco University (USF), Bragança Paulista, São Paulo 12916-900, Brazil
4
Department of Surgery, University of Campinas (UNICAMP), Campinas, São Paulo 12916-900, Brazil
5
Nano-Inspired Biomedicine Lab, Istituto di Ricerca Pediatrica-Città della Speranza, 35127 Padua, Italy
6
First Surgery Clinic, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua 35128, Italy
*
Author to whom correspondence should be addressed.
Received: 6 November 2018 / Revised: 4 December 2018 / Accepted: 4 December 2018 / Published: 6 December 2018
Full-Text   |   PDF [917 KB, uploaded 16 December 2018]   |  
  |   Review Reports

Abstract

Background: There are currently no blood-based biomarkers for early diagnosis of colorectal cancer. Previous research has suggested that very-long-chain dicarboxylic acid (VLCDCA) 28:4 might be such a biomarker. Methods: Using high-resolution mass spectrometry, we analyzed VLCDCA 28:4 in the plasma of colorectal cancer patients in Italian [n = 62] and Brazilian [n = 52] cohorts. Additionally, we investigated individuals diagnosed with familial adenomatous polyposis (FAP; n = 27), one of the most important clinical forms of inherited susceptibility to colorectal cancer. Results: Decrements in plasma levels of VLCDCA 28:4 were monitored in colorectal cancer patients. These decreases were independent of the stage of tumor development and the individual’s age. However, no decrements in VLCDCA 28:4 were monitored in FAP patients. Conclusions: The plasma levels of VLCDCA 28:4 represent a potential biomarker of sporadic colorectal cancer. In addition, it is possible that resupply of this anti-inflammatory lipid may represent a new therapeutic strategy for CRC and inflammatory disorders. View Full-Text
Keywords: colorectal cancer; inflammation; very-long-chain dicarboxylic acid 28:4; familial adenomatous polyposis; high-resolution mass spectrometry; cancer biomarker colorectal cancer; inflammation; very-long-chain dicarboxylic acid 28:4; familial adenomatous polyposis; high-resolution mass spectrometry; cancer biomarker
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wood, P.L.; Donohue, M.M.; Cebak, J.E.; Beckmann, T.G.; Messias, M.C.F.; Credidio, L.; Coy, C.S.R.; Carvalho, P.O.; Crotti, S.; D’Aronco, S.; Urso, E.D.; Agostini, M. Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts. Metabolites 2018, 8, 91.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top